Baloxavir marboxil
2 Inquiries
1985606-14-1
Pharmaceutical Grade
99%
As per Customer's requirement
2021-08-31
API,Intermediate
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial ReferenceBaloxavir marboxil is an antiviral drug developed by Shionogi Co., a Japanese pharmaceutical company and Roche for the treatment of influenza A and influenza B infections. The drug was initially approved for use in Japan in February 2018 and approved by the FDA on October 24, 2018, for the treatment of acute uncomplicated influenza in patients 12 years of age and older who have been symptomatic for no more than 48 hours. Baloxavir marboxil, a cap-endonuclease inhibitor, has a unique mechanism of action when compared to the currently existing neuraminidase inhibitor drug class used to treat influenza infections.|Baloxavir is an inhibitor of the influenza cap-dependent endonuclease enzyme and is used as therapy of influenza A and B. Baloxavir is given as a single, one-time dose and has not been associated with serum enzyme elevations or with clinically apparent liver injury.|Baloxavir Marboxil is an orally bioavailable prodrug and influenza cap-dependent endonuclease (CEN) inhibitor, with antiviral activity. Upon administration of baloxavir marboxil, the agent is converted by hydrolysis to its active metabolite baloxavir. Baloxavir targets, binds to and inhibits the CEN activity of the influenza polymerase acidic (PA) protein, an influenza virus-specific enzyme in the viral RNA polymerase complex required for the initiation of influenza gene transcription. By inhibiting PA endonuclease, influenza virus mRNA replication is halted. This reduces viral load and prevents further influenza infection.Basic Info
-
Product Name:
Baloxavir marboxil
Other Name:CS-2794;S-033188;S-033188;XOFLUZA;Xofluza;aloxavir marboxil;PubChem ID: 124081896;Baloxavir marboxil;baloxavir marboxil S-033188
CAS No.:1985606-14-1
Molecular Formula:C27H23F2N3O7S
InChIKeys:HKVHAHZGMLTCDW-BWFGELNCSA-N
Molecular Weight:571.55
Exact Mass:571.55
EC Number:606-227-7
UNII:505CXM6OHG
NCI Thesaurus Code:C166177
Color/Form:White to yellow
ATC Code:J - Antiinfectives for systemic use
Categories:
Characteristics-
XLogP3:
2.24
Density:1.57±0.1 g/cm3(Predicted)
Boiling Point:712.8±70.0 °C(Predicted)
Water Solubility:Soluble in water
PKA:-1.46±0.40(Predicted)
Critical Temperature & Pressure:Sealed in dry,Store in freezer, under -20°C
-
-
Seller Information
-
Business Type:
Distributor
-
Main Products:
API,Intermediate
-
Payment Terms:
TT against copy of documents,L/C
-
Average lead Time:
30
-
Total Annual Revenue:
Above $100 million
-
Total Employees:
201-300
About Echemi Pharmaceutical
Echemi’s philosophy is to seek for higher quality, to explore frontier area. The progress of human society, the extension of life expectancy, and the conquest of disease are all derived from the numerous businesses and individuals who have quietly dedicated themselves in the pharmaceutical industry. It’s the controlling of supply chain quality that ensures the efficacy. It’s the continuous exploration that promotes the development of the pharmaceutical industry and benefits more future generations. The pursuit of high quality requires all partners of Echemi Pharmaceutical to be screened, whether its certificate, qualification or scale. In the field of renewal, we will embrace all new changes and make more contributions to the development of pharmaceutical industry.
Advantage for Pharmaceutical
• Having been working in pharmaceutical field for more then 15 years, we have experienced regulatory team, quality control team, sourcing team, technical support team, and logistics team. And we are familiar with the regulatory requirements from different areas, can offer tailored service for our customers.
• We have hundreds of strategic partners for APIs, intermediates, and custom synthesis. All of our partners are ready to support our customers with documents, and be audited.
• We can offer custom synthesis for some new chemical structures and some materials which there are no reliable suppliers.
Product Category
We care for human and animal health and we are committed to creating a better social environment.
• Human API
• Intermediate
• Veterinary API
• Agrochemical
• Fine Chemical
• Custom Synthesis
-
-
Inquiry History2 Inquiries
Country Product Purchase Quantity Date Posted 
United States
Baloxavir marboxil Pharmaceutical Raw Powder CAS
100 G Aug 21, 2025 
Egypt
Baloxavir Marboxil
3 KG Jun 5, 2026 Post an enquiry for this product